Severe asthma
Conditions
Interventions
None listed
Sponsors
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
Boston Scietific Japan Co. Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Uncontrolled severe asthma patients treated with high dose inhaled corticosteroid and long-acting beta2-agonists 2. Eligible for fiberoptic bronchoscopy
Exclusion criteria
Exclusion criteria: 1. Have a pacemaker, implantable cardioverter defibrillator, or other implantable electronic device. 2. Have a known sensitivity to medications required to perform bronchoscopy, including lidocaine, atropine, and benzodiazepines. 3. Have been previously treated with BT 4. Active respiratory infection 5. Asthma exacerbation or changing doseof systemic corticosteroids for asthma in the past 14 days 6. Known coagulopathy. As with other bronchoscopic procedures, patients should stop taking anticoagulants, antiplatelet agents, aspirin, and NSAIDS before the procedure with physician guidance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QOL (quality of life) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Asthma exacerbation 2.Emergency room visits 3.Unscheduled physician office visits 4.Hospitalization frequency 5.Hospitalizations 6.Days missed from work/school 7.Physician's Global Evaluation of Treatment Effectiveness (GETE) assessment 8.Therapeutic drug use 9.Pulmonary function 10.Adverse events | — |
Countries
Japan
Contacts
Public ContactAkihiro Takemasa
Dokkyo Medical University School of Medicine Department of Pulmonary Medicine and Clinical Immunology
Outcome results
None listed